Mid-Day Market Update: Gold Rises 2%; IronNet Shares Plummet
Midway through trading Thursday, the Dow traded up 0.67% to 36,166.39 while the NASDAQ fell 0.63% to 15,467.79. The S&P also rose, gaining 0.20% to 4,719.09.
Mid-Morning Market Update: Markets Mixed; Accenture Beats Q1 Estimates
Following the market opening Thursday, the Dow traded up 0.49% to 36,102.31 while the NASDAQ fell 0.68% to 15,460.25. The S&P also rose, gaining 0.08% to 4,713.43.
18 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce proteinuria in lgA nephropathy.
Calliditas Says FDA Grants Co Accelerated Approval Of TARPEYO To Reduce Proteinuria In IgA Nephropathy
https://www.calliditas.se/en/fda-grants-calliditas-therapeutics-accelerated-approval-of-tarpeyo-budesonide-to-reduce-proteinuria-in-iga-nephropathy-3927/
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound.
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date period to 45. This is just one short of NME approvals received for the same period last year.
91 Biggest Movers From Yesterday
Gainers
NuZee, Inc. (NASDAQ: NUZE) shares jumped 164.5% to settle at $5.29 on Thursday. NuZee manufacturing partner, Cuvee Coffee, reported an expansion into select Walmart stores nationwide.